Quarterly ResultAug 5, 2026, 04:31 PM
Cytek Biosciences Q2 Revenue $48.1M, Raises FY26 Guidance
AI Summary
Cytek Biosciences reported second quarter 2026 financial results, with total revenue increasing 6% year-over-year to $48.1 million. The company launched new products, Cytek Borealis™ and Cytek Aurora™ Evo configurations, and saw recurring revenue grow to $18.5 million. Despite improved GAAP gross profit and margin, the net loss widened to $12.2 million. Cytek Biosciences also updated its full-year 2026 revenue guidance, raising the midpoint by $1 million to a range of $207 million to $212 million.
Key Highlights
- Total revenue for Q2 2026 was $48.1 million, a 6% increase year-over-year.
- Launched Cytek Borealis™, a new 7-laser full spectrum flow cytometer.
- Introduced Cytek Aurora™ Evo instrument configurations with expanded automation.
- Total recurring revenue reached $18.5 million in Q2 2026, representing 35% of total revenue on a trailing-12-month basis.
- GAAP gross profit was $28.3 million, a 19% increase, with a 59% margin in Q2 2026.
- Net loss for Q2 2026 was $12.2 million, compared to a net loss of $5.6 million in Q2 2025.
- Updated full-year 2026 revenue guidance to $207 million to $212 million, raising the midpoint by $1 million.
- Cash, cash equivalents and marketable securities totaled $262.0 million as of June 30, 2026.
Price Impact
More from CTKB